A detailed history of Cutler Group LP transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Cutler Group LP holds 100 shares of RAPT stock, worth $108. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Holding current value
$108
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$6.87 - $26.45 $687 - $2,645
100 New
100 $0
Q4 2021

Jan 18, 2022

SELL
$29.5 - $39.5 $44,250 - $59,250
-1,500 Closed
0 $0
Q3 2021

Oct 26, 2021

SELL
$29.86 - $39.47 $241,447 - $319,154
-8,086 Reduced 84.35%
1,500 $46,000
Q2 2021

Jul 19, 2021

BUY
$17.99 - $40.02 $163,457 - $363,621
9,086 Added 1817.2%
9,586 $304,000
Q4 2020

Jan 21, 2021

BUY
$15.89 - $40.87 $7,945 - $20,435
500 New
500 $9,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $32M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.